ANDA 62464, held by Bristol. Cephalothin Sodium.
As of Nov 15, 2026, ANDA 62464 (Cephalothin Sodium), held by Bristol, was not approved, with 0 approved supplements and 0 published complete response letters.
| Cephalothin SodiumEQ 1GM BASE/VIAL · injectable;injection | Cephalothin Sodium | Discontinued |
| Cephalothin SodiumEQ 2GM BASE/VIAL · injectable;injection | Cephalothin Sodium | Discontinued |
| Cephalothin SodiumEQ 4GM BASE/VIAL · injectable;injection | Cephalothin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
